Similar Papers

Paper Title
Journal
Date
Author
Abstract 3804: The potent AXL kinase inhibitor, TP-0903, is active in pre-clinical models of EGFR positive non-small cell lung cancer
Ryan Mangelson ... Ethika Tyagi
-
Ryan Mangelson, et. al.Ryan Mangelson ... Ethika Tyagi
01 Jul 2019
Abstract 3804: The potent AXL kinase inhibitor, TP-0903, is active in pre-clinical models of EGFR positive non-small cell lung cancer
Ryan Mangelson ... Ethika Tyagi
Cancer Research | VOL. 79
Ryan Mangelson, et. al.Ryan Mangelson ... Ethika Tyagi
01 Jul 2019
A Real-world Study on the Expression Characteristics of PD-L1 in Patients with Advanced EGFR Positive NSCLC and Its Relationship with the Therapeutic Efficacy of EGFR-TKIs
Ran Chen ... Bo Hu
Zhongguo fei ai za zhi = Chinese journal of lung cancer | VOL. 26
Ran Chen, et. al.Ran Chen ... Bo Hu
20 Mar 2023
The prognostic role of body-mass index (BMI) for advanced EGFR positive non-small cell lung cancer (NSCLC) patients treated with osimertinib.
Andrea De Giglio ... Francesco Gelsomino
Journal of Clinical Oncology | VOL. 39
Andrea De Giglio, et. al.Andrea De Giglio ... Francesco Gelsomino
20 May 2021
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Reply to the Letter to the Editor regarding ‘PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?’ by T. Nishimura and H. Fujimoto
E Felip ... S.-H Lee
Annals of Oncology | VOL. 36
E Felip, et. al.E Felip ... S.-H Lee
01 Feb 2025
Expanding the role of CDK4/6 inhibitors in early breast cancer: insights from the NATALEE trial
Marcela Carausu ... Michail Ignatiadis
Annals of Oncology | VOL. 36
Marcela Carausu, et. al.Marcela Carausu ... Michail Ignatiadis
01 Feb 2025
FOxTROT: is anti-EGFR a good dancing partner?
Clara Montagut ... Joana Vidal
Annals of Oncology | VOL. -
Clara Montagut, et. al.Clara Montagut ... Joana Vidal
01 Feb 2025
Table of Contents
-
Annals of Oncology | VOL. 36
--
01 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.